Adenosine A1 receptors, KATP channels, and ischemic preconditioning in dogs

Am J Physiol. 1993 May;264(5 Pt 2):H1327-36. doi: 10.1152/ajpheart.1993.264.5.H1327.

Abstract

The objective of the present study was to characterize the role of adenosine in myocardial ischemic preconditioning in the canine heart. Preconditioning with 5 min of ischemia resulted in a marked reduction in infarct size after 60 min of left circumflex coronary artery occlusion and 5 h of reperfusion in barbital-anesthetized dogs compared with dogs that were not preconditioned (4.8 +/- 1.9 vs. 27.9 +/- 4.5%; P < 0.05). Pretreatment with either the nonselective adenosine receptor antagonist PD 115199 or the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine blocked this protective effect, although in the absence of preconditioning neither of the antagonists affected infarct size. Intracoronary infusion of two different doses of adenosine or dipyridamole over a 5-min period before a prolonged 60-min occlusion period did not mimic preconditioning; however, intracoronary infusion of a combination of adenosine and dipyridamole produced a significant reduction in infarct size (13.6 +/- 4.1%), which was abolished by pretreatment with the ATP-dependent potassium (KATP) channel antagonist glibenclamide. These results suggest that activation of adenosine A1 receptors produces myocardial preconditioning in the canine heart by opening KATP channels.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenosine / antagonists & inhibitors
  • Adenosine / pharmacology
  • Adenosine Triphosphate / physiology*
  • Animals
  • Blood Glucose / analysis
  • Coronary Circulation / drug effects
  • Coronary Disease / metabolism*
  • Dogs
  • Female
  • Glyburide / pharmacology
  • Hemodynamics / drug effects
  • Male
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion*
  • Potassium Channels / metabolism*
  • Purines / pharmacology
  • Receptors, Purinergic / metabolism*
  • Sulfonamides / pharmacology
  • Xanthines / pharmacology

Substances

  • Blood Glucose
  • Potassium Channels
  • Purines
  • Receptors, Purinergic
  • Sulfonamides
  • Xanthines
  • N-(2-(dimethylamino)ethyl)-N-methyl-4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)benzenesulfonamide
  • Adenosine Triphosphate
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Adenosine
  • Glyburide